168 related articles for article (PubMed ID: 18470848)
1. Enhanced iodide sequestration by 3-biphenyl-5,6-dihydroimidazo[2,1-b]thiazole in sodium/iodide symporter (NIS)-expressing cells.
Lecat-Guillet N; Ambroise Y
ChemMedChem; 2008 Aug; 3(8):1211-6. PubMed ID: 18470848
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of imidazo[2,1-b]thiazoles as iodide efflux inhibitors in thyrocytes.
Lecat-Guillet N; Ambroise Y
ChemMedChem; 2009 Nov; 4(11):1819-30. PubMed ID: 19780099
[TBL] [Abstract][Full Text] [Related]
3. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer.
Kakinuma H; Bergert ER; Spitzweg C; Cheville JC; Lieber MM; Morris JC
Cancer Res; 2003 Nov; 63(22):7840-4. PubMed ID: 14633711
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy and noninvasive imaging with a dual therapeutic vector expressing MDR1 short hairpin RNA and a sodium iodide symporter.
Park SY; Kwak W; Thapa N; Jung MY; Nam JO; So IS; Kim SY; Yoo J; Lee J; Kim IS
J Nucl Med; 2008 Sep; 49(9):1480-8. PubMed ID: 18703598
[TBL] [Abstract][Full Text] [Related]
5. Iodide kinetics and dosimetry in vivo after transfer of the human sodium iodide symporter gene in rat thyroid carcinoma cells.
Haberkorn U; Beuter P; Kübler W; Eskerski H; Eisenhut M; Kinscherf R; Zitzmann S; Strauss LG; Dimitrakopoulou-Strauss A; Altmann A
J Nucl Med; 2004 May; 45(5):827-33. PubMed ID: 15136633
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer.
Kogai T; Taki K; Brent GA
Endocr Relat Cancer; 2006 Sep; 13(3):797-826. PubMed ID: 16954431
[TBL] [Abstract][Full Text] [Related]
7. Characterization of small-molecule inhibitors of the sodium iodide symporter.
Lindenthal S; Lecat-Guillet N; Ondo-Mendez A; Ambroise Y; Rousseau B; Pourcher T
J Endocrinol; 2009 Mar; 200(3):357-65. PubMed ID: 19066290
[TBL] [Abstract][Full Text] [Related]
8. Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells.
Schipper ML; Weber A; Béhé M; Göke R; Joba W; Schmidt H; Bert T; Simon B; Arnold R; Heufelder AE; Behr TM
Cancer Res; 2003 Mar; 63(6):1333-8. PubMed ID: 12649195
[TBL] [Abstract][Full Text] [Related]
9. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer.
Scholz IV; Cengic N; Baker CH; Harrington KJ; Maletz K; Bergert ER; Vile R; Göke B; Morris JC; Spitzweg C
Gene Ther; 2005 Feb; 12(3):272-80. PubMed ID: 15510175
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy with sodium/iodide symporter in hepatocarcinoma.
Haberkorn U
Exp Clin Endocrinol Diabetes; 2001; 109(1):60-2. PubMed ID: 11573143
[TBL] [Abstract][Full Text] [Related]
11. Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose.
Haberkorn U; Kinscherf R; Kissel M; Kübler W; Mahmut M; Sieger S; Eisenhut M; Peschke P; Altmann A
Gene Ther; 2003 May; 10(9):774-80. PubMed ID: 12704416
[TBL] [Abstract][Full Text] [Related]
12. Xanthohumol stimulates iodide uptake in rat thyroid-derived FRTL-5 cells.
Radović B; Schmutzler C; Köhrle J
Mol Nutr Food Res; 2005 Sep; 49(9):832-6. PubMed ID: 16092068
[TBL] [Abstract][Full Text] [Related]
13. The Q267E mutation in the sodium/iodide symporter (NIS) causes congenital iodide transport defect (ITD) by decreasing the NIS turnover number.
De La Vieja A; Ginter CS; Carrasco N
J Cell Sci; 2004 Feb; 117(Pt 5):677-87. PubMed ID: 14734652
[TBL] [Abstract][Full Text] [Related]
14. Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line.
Jeong H; Kim YR; Kim KN; Choe JG; Chung JK; Kim MK
Nucl Med Biol; 2006 Oct; 33(7):875-82. PubMed ID: 17045167
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of iodide uptake and efflux in various human thyroid cancer cells by expressing sodium iodide symporter gene via a recombinant adenovirus.
Lee WW; Lee B; Kim SJ; Jin J; Moon DH; Lee H
Oncol Rep; 2003; 10(4):845-9. PubMed ID: 12792733
[TBL] [Abstract][Full Text] [Related]
16. In vitro cytotoxicity of (211)at-astatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter.
Carlin S; Akabani G; Zalutsky MR
J Nucl Med; 2003 Nov; 44(11):1827-38. PubMed ID: 14602867
[TBL] [Abstract][Full Text] [Related]
17. Small-molecule inhibitors of sodium iodide symporter function.
Lecat-Guillet N; Merer G; Lopez R; Pourcher T; Rousseau B; Ambroise Y
Chembiochem; 2008 Apr; 9(6):889-95. PubMed ID: 18307189
[TBL] [Abstract][Full Text] [Related]
18. Mitogen-activated protein kinase signaling enhances sodium iodide symporter function and efficacy of radioiodide therapy in nonthyroidal cancer cells.
Jung KH; Paik JY; Ko BH; Lee KH
J Nucl Med; 2008 Dec; 49(12):1966-72. PubMed ID: 18997042
[TBL] [Abstract][Full Text] [Related]
19. Genetically targeted radiotherapy of head and neck squamous cell carcinoma using the sodium-iodide symporter (NIS).
Gaut AW; Niu G; Krager KJ; Graham MM; Trask DK; Domann FE
Head Neck; 2004 Mar; 26(3):265-71. PubMed ID: 14999802
[TBL] [Abstract][Full Text] [Related]
20. Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma.
Willhauck MJ; Sharif Samani BR; Klutz K; Cengic N; Wolf I; Mohr L; Geissler M; Senekowitsch-Schmidtke R; Göke B; Morris JC; Spitzweg C
Gene Ther; 2008 Feb; 15(3):214-23. PubMed ID: 17989705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]